|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.300 ILa | -7.14% |
|
-7.14% | -31.58% |
| Capitalization | 14.07M 4.99B 12.15M 11.4M 10.34M 19.15M 1.2B 21.55M 133M 51.79M 553M 52.8M 51.69M 2.02B | P/E ratio 2025 * |
-
| P/E ratio 2026 * | - |
|---|---|---|---|---|---|
| Enterprise value | 14.07M 4.99B 12.15M 11.4M 10.34M 19.15M 1.2B 21.55M 133M 51.79M 553M 52.8M 51.69M 2.02B | EV / Sales 2025 * |
-
| EV / Sales 2026 * | 1.31x |
| Free-Float |
75.17% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Can-Fite BioPharma Ltd.
More press releases
| 1 day | -7.14% | ||
| 1 week | -7.14% | ||
| 1 month | -7.14% | ||
| 3 months | -31.58% | ||
| 6 months | -31.58% | ||
| Current year | -31.58% |
| 1 week | 1.3 |  | 1.4 |
| 1 month | 1.3 | | 1.4 |
| Current year | 1.3 | | 2.7 |
| 1 year | 1.3 | | 5.6 |
| 3 years | 1.3 | | 13.8 |
| 5 years | 1.3 | | 47.5 |
| 10 years | 1.3 | | 1,029 |
| Manager | Title | Age | Since |
|---|---|---|---|
Motti Farbstein
CEO | Chief Executive Officer | 60 | 2023-06-29 |
Pnina Fishman
CEO | Chief Executive Officer | 75 | 2010-05-09 |
Zivit Harpaz
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Pnina Fishman
CHM | Chairman | 75 | 2023-06-29 |
Abraham Sartani
BRD | Director/Board Member | 77 | 2000-12-31 |
Guy Regev
BRD | Director/Board Member | 56 | 2011-06-30 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -7.14% | -7.14% | -56.67% | -87.85% | 15.52M | ||
| +0.08% | -2.10% | -15.81% | -11.18% | 76.01B | ||
| -1.34% | +2.90% | +39.05% | +26.88% | 54.19B | ||
| -0.76% | +1.30% | +24.47% | +101.02% | 35.97B | ||
| -0.56% | +0.34% | -41.39% | -33.01% | 19.5B | ||
| +1.00% | +8.75% | +131.71% | +201.87% | 16.82B | ||
| +0.61% | +7.74% | +44.80% | +849.13% | 15.92B | ||
| -0.04% | -.--% | +90.76% | +148.72% | 14.02B | ||
| +0.54% | +2.67% | +16.38% | -1.68% | 13.33B | ||
| -1.29% | -6.50% | -0.94% | -28.26% | 11.87B | ||
| Average | -0.89% | +1.72% | +23.24% | +116.57% | 25.76B | |
| Weighted average by Cap. | -0.34% | +0.98% | +20.94% | +86.30% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | - | 10.78M 3.83B 9.31M 8.73M 7.92M 14.67M 922M 16.51M 102M 39.68M 424M 40.45M 39.59M 1.55B |
| Net income | -9.07M -3.22B -7.83M -7.35M -6.66M -12.34M -776M -13.89M -85.63M -33.38M -357M -34.03M -33.31M -1.3B | -627K -222M -541K -508K -461K -853K -53.63M -960K -5.92M -2.31M -24.66M -2.35M -2.3M -89.96M |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
5
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-06-12 | 1.300 ILa | -7.14% | 14,285,410 |
| 25-06-11 | 1.400 ILa | +7.69% | 3,301,428 |
| 25-06-10 | 1.300 ILa | -7.14% | 7,942,639 |
| 25-06-09 | 1.400 ILa | 0.00% | 5,058,564 |
| 25-06-08 | 1.400 ILa | 0.00% | 2,036,636 |
Delayed Quote TEL AVIV STOCK EXCHANGE, June 12, 2025 at 10:24 am EDT
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CANF Stock
Select your edition
All financial news and data tailored to specific country editions
